Skip to main navigation

Top bar

Biogen.com Information Request Sign up for Alerts Search

Investor Relations

Overview

News

Events Presentations

SEC Filings Annual Reports

Stock Quote & Chart Analyst Coverage Investor FAQs

Governance Documents Committee Composition & Charters Leadership Code of Business Conduct Contact the Board

News

News

News Category

Year

January 3, 2019

First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis

December 17, 2018

Biogen to Present at the 37th Annual J.P. Morgan Healthcare Conference

December 17, 2018

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

December 10, 2018

Biogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019

December 6, 2018

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

November 29, 2018

International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product

November 26, 2018

Biogen to Present at the Evercore ISI HealthConX

November 19, 2018

Biogen To Host Investor Webcast On Its Multiple Sclerosis Portfolio On December 12, 2018

October 26, 2018

Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)

October 25, 2018

Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 11 - 20 of 660

Footer

Investors
Careers
Our Stories
Contact Us

Follow us

Bottom

Privacy Policy
Terms & Conditions
Forward-Looking Statements
Community Guidelines

Investor Relations

Overview

News

Events & Presentations

Events
Presentations

Financials

SEC Filings
Annual Reports

Stock Information

Stock Quote & Chart
Analyst Coverage
Investor FAQs

Corporate Governance

Governance Documents
Committee Composition & Charters
Leadership
Code of Business Conduct
Contact the Board

Top bar

Biogen.com

Information Request

Sign up for Alerts

Search

Follow us